Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net loss	$ (8,356)	$ (5,724)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	490	492
Non-cash lease expense	78	71
Stock-based compensation expense	631	644
Change in fair value of stock warrants		(27)
Change in fair value of contingent consideration	299	(858)
Other non-cash reconciling items	16	(2)
Change in operating assets and liabilities:
Prepaid expenses, other current assets and other assets	(334)	114
Accounts payable	1,001	(1,046)
Accrued compensation	(954)	(130)
Accrued clinical trial site costs	309	101
Operating lease liabilities	(116)	(34)
Other liabilities	208	37
Net cash used in operating activities	(6,728)	(6,362)
Cash flows from financing activities:
Proceeds from sale of common stock and pre-funded warrants, net of costs		14,048
Tax withholding payments for net share-settled equity awards		(16)
Net cash provided by financing activities		14,032
Net (decrease) increase in cash and cash equivalents	(6,728)	7,670
Cash and cash equivalents, beginning of period	14,602	21,304
Cash and cash equivalents, end of period	$ 7,874	28,974
Supplemental disclosure of non-cash financing information
Unpaid costs for issuing common stock and pre-funded warrants		$ 282